Qiagen : Fantasy about FY 2022 should not blur the vision for FY 2023…
>Set for a strong FY 2022 - We now estimate a 6% forex headwind for FY 2022 vs 4% previously. We have made another upward adjustment to our FY 2022 forecasts by 1% on sales, adj. EBIT and by 4% on adj. EPS due to a better performance on Covid-related products ($ 470m vs $ 370m previously). We are now forecasting sales of $ 2.272bn excl. forex ($ 2.136bn reported) and adj. EPS of $ 2.39 excl. forex ($ 2.27 in US $), which compares well with the guidance (at least $ 2.2...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.